And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...

Samsung Bioepis, a biosimilar drug developer under Samsung Group, said Tuesday it has received approval to sell its biosimilar treatment for autoimmune disease in Japan.

SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will ...

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...

Amine Mojito, the French internet personality known as Ilan M, was sentenced by the Paris Criminal Court on Oct. 3 Luke Chinman is a writer at PEOPLE. He joined PEOPLE in 2024. His work has previously ...

Humira (adalimumab) is used to treat several autoimmune conditions. The drug typically stays in your system for a few months after your final dose. This article explains how long Humira may remain in ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...

The U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Celltrion’s YUFLYMA (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors ...

The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...